Cell and Molecular Biology Lab, Institute of Zoology, University of the Punjab, Q-A Campus, Lahore 54590, Pakistan.
Department of Pathology and Microbiology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.
Mediators Inflamm. 2021 Feb 24;2021:6613786. doi: 10.1155/2021/6613786. eCollection 2021.
Tacrolimus (TAC) is an immunosuppressive drug, optimally used for liver, kidney, and heart transplant to avoid immune rejection. In retrospect, a multitude of studies have reported effects of TAC, such as nephrotoxicity, diabetes, and other complications. However, limited information is available regarding short-term exposure of TAC on the liver. Therefore, the present study was designed to unravel the effects of short-term exposure of TAC on a rat model. The animal model was established by TAC administration for 6, 12, 24, and 48 h time points. Liver histopathological changes were observed with PAS-D, reticulin stain, and immunostaining of PCNA and CK-7 coupled with glycogen quantification in a liver homogenate. TUNEL assay was performed to evaluate the DNA damage in the liver. Concentration of GSH and activities of SOD and CAT in the serum were measured to assess the antioxidant status, whereas liver tissue MDA level was measured as a biomarker of oxidative stress. Hepatic gene expression analysis of IL-10, IL-13, SOCS-2, and SOCS-3 was performed by RT-PCR. Results revealed marked changes in liver architecture of all TAC-treated groups, as evidenced by sinusoid dilation, hepatocyte derangement, glycogen deposition, and collapsed reticulin fibers. Significant increase in PCNA and CK-7 immunostaining along with the presence of TUNEL-positive cells was revealed in treatment groups as compared to the control group. Serum antioxidant enzyme status was markedly decreased, whereas the liver MDA level was increased in TAC treatment groups indicating oxidative stress induction. The gene expression profile of cytokines was significantly upregulated in treatment groups highlighting an inflammatory response. In conclusion, results of the current study propose that even a short-term TAC exposure can induce change in antioxidant status and lipid peroxidation. Therefore, these factors should be considered to avoid and minimize immunosuppression-related issues in a prolonged course of treatment.
他克莫司(TAC)是一种免疫抑制剂,最佳用于肝、肾和心脏移植,以避免免疫排斥。回顾性研究表明,TAC 具有多种作用,如肾毒性、糖尿病和其他并发症。然而,关于 TAC 短期暴露对肝脏的影响,信息有限。因此,本研究旨在揭示 TAC 短期暴露对大鼠模型的影响。通过给予 TAC 6、12、24 和 48 小时时间点来建立动物模型。用 PAS-D、网状纤维染色、PCNA 和 CK-7 的免疫染色以及肝匀浆中糖原定量来观察肝组织病理变化。进行 TUNEL 检测评估肝内 DNA 损伤。测定血清中 GSH 浓度、SOD 和 CAT 活性以评估抗氧化状态,同时测定肝组织 MDA 水平作为氧化应激的生物标志物。通过 RT-PCR 分析肝组织中 IL-10、IL-13、SOCS-2 和 SOCS-3 的基因表达。结果显示,所有 TAC 处理组的肝结构均发生明显变化,表现为窦扩张、肝细胞排列紊乱、糖原沉积和网状纤维塌陷。与对照组相比,治疗组 PCNA 和 CK-7 免疫染色明显增加,同时 TUNEL 阳性细胞增多。TAC 处理组血清抗氧化酶活性显著降低,而肝 MDA 水平升高,表明氧化应激诱导。治疗组细胞因子的基因表达谱明显上调,提示炎症反应。总之,本研究结果表明,即使是短期 TAC 暴露也会引起抗氧化状态和脂质过氧化的变化。因此,在长期治疗过程中应考虑这些因素,以避免和最小化免疫抑制相关问题。